IMVT

Announcements

Nothing here yet

Daily updates

• Immunovant reported that IMVT-1402 failed to achieve statistical significance on the Week 12 CLASI-A primary endpoint in cutaneous lupus erythematosus, resulting in termination of the CLE program.Sep 23, 2026

FDA designations

Nothing here yet

News

• Immunovant reports topline results from a proof-of-concept study of IMVT-1402 in cutaneous lupus erythematosusSep 23, 2026
• Immunovant reported Phase 3 results for batoclimab in thyroid eye diseaseApr 2, 2026
• Immunovant unveils durability and treatment-free six-month remission data with potential to change treatment paradigm for uncontrolled Graves' disease patientsSep 4, 2025